| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | bevacizumab (Avastin®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 40 |
| Indication | In combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/01/2007 |
| NICE guidance | TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |